German biotech Adrenomed has proof-of-concept data showing its sepsis drug can cut mortality by 67%. Now, it needs money to move the candidate into Phase IIb/III trials.
In a video call with German biotech Adrenomed AG, the company’s CEO Richard Jones made a striking observation: 400people would die from sepsis or septic shock during our 20-minute conversation.
The unmet need to treat sepsis is so great that the World Health Organization has made it a global health...
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
